
Duchenne Muscular Dystrophy Global Market Report 2025
Description
Duchenne Muscular Dystrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on duchenne muscular dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Where is the largest and fastest growing market for duchenne muscular dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Markets Covered:1) By Therapy: Mutation Suppression; Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies; Steroid Therapy
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs); Small Molecules; Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies; Combination Therapies; Clinical Trials And Investigational Drugs
Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; PerkinElmer Inc.; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
This report focuses on duchenne muscular dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for duchenne muscular dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Markets Covered:1) By Therapy: Mutation Suppression; Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies; Steroid Therapy
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs); Small Molecules; Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies; Combination Therapies; Clinical Trials And Investigational Drugs
Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; PerkinElmer Inc.; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
175 Pages
- 1. Executive Summary
- 2. Duchenne Muscular Dystrophy Market Characteristics
- 3. Duchenne Muscular Dystrophy Market Trends And Strategies
- 4. Duchenne Muscular Dystrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
- 5. Global Duchenne Muscular Dystrophy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Duchenne Muscular Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Duchenne Muscular Dystrophy Market Growth Rate Analysis
- 5.4. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Duchenne Muscular Dystrophy Total Addressable Market (TAM)
- 6. Duchenne Muscular Dystrophy Market Segmentation
- 6.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Mutation Suppression
- Exon Skipping Approach
- 6.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Molecular Based Therapies
- Steroid Therapy
- 6.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes Of Administration
- 6.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- 6.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End-Users
- 6.6. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antisense Oligonucleotides (ASOs)
- Small Molecules
- Gene Therapy
- 6.7. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Exon-Skipping Therapies
- Combination Therapies
- Clinical Trials And Investigational Drugs
- 7. Duchenne Muscular Dystrophy Market Regional And Country Analysis
- 7.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8. Asia-Pacific Duchenne Muscular Dystrophy Market
- 8.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 9. China Duchenne Muscular Dystrophy Market
- 9.1. China Duchenne Muscular Dystrophy Market Overview
- 9.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 10. India Duchenne Muscular Dystrophy Market
- 10.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Japan Duchenne Muscular Dystrophy Market
- 11.1. Japan Duchenne Muscular Dystrophy Market Overview
- 11.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. Australia Duchenne Muscular Dystrophy Market
- 12.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13. Indonesia Duchenne Muscular Dystrophy Market
- 13.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. South Korea Duchenne Muscular Dystrophy Market
- 14.1. South Korea Duchenne Muscular Dystrophy Market Overview
- 14.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Western Europe Duchenne Muscular Dystrophy Market
- 15.1. Western Europe Duchenne Muscular Dystrophy Market Overview
- 15.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. UK Duchenne Muscular Dystrophy Market
- 16.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Germany Duchenne Muscular Dystrophy Market
- 17.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. France Duchenne Muscular Dystrophy Market
- 18.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Italy Duchenne Muscular Dystrophy Market
- 19.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. Spain Duchenne Muscular Dystrophy Market
- 20.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Duchenne Muscular Dystrophy Market
- 21.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview
- 21.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. Russia Duchenne Muscular Dystrophy Market
- 22.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. North America Duchenne Muscular Dystrophy Market
- 23.1. North America Duchenne Muscular Dystrophy Market Overview
- 23.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. USA Duchenne Muscular Dystrophy Market
- 24.1. USA Duchenne Muscular Dystrophy Market Overview
- 24.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. Canada Duchenne Muscular Dystrophy Market
- 25.1. Canada Duchenne Muscular Dystrophy Market Overview
- 25.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. South America Duchenne Muscular Dystrophy Market
- 26.1. South America Duchenne Muscular Dystrophy Market Overview
- 26.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Brazil Duchenne Muscular Dystrophy Market
- 27.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Middle East Duchenne Muscular Dystrophy Market
- 28.1. Middle East Duchenne Muscular Dystrophy Market Overview
- 28.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29. Africa Duchenne Muscular Dystrophy Market
- 29.1. Africa Duchenne Muscular Dystrophy Market Overview
- 29.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 30. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles
- 30.1. Duchenne Muscular Dystrophy Market Competitive Landscape
- 30.2. Duchenne Muscular Dystrophy Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. PerkinElmer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
- 31. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies
- 31.1. PTC Therapeutics Inc.
- 31.2. Asklepios BioPharmaceutical Inc.
- 31.3. Catabasis Pharmaceuticals Inc.
- 31.4. Wave Life Sciences Ltd.
- 31.5. Bristol Myers Squibb Company
- 31.6. BridgeBio Pharma Inc.
- 31.7. Rocket Pharmaceuticals Inc.
- 31.8. Italfarmaco SpA
- 31.9. Solid Biosciences Inc.
- 31.10. Avidity Biosciences Inc.
- 31.11. Fulcrum Therapeutics Inc.
- 31.12. Akashi Therapeutics Inc.
- 31.13. WAVE Life Sciences Ltd.
- 31.14. Capricor Therapeutics Inc.
- 31.15. Santhera Pharmaceuticals Holding
- 32. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking And Dashboard
- 33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market
- 34. Recent Developments In The Duchenne Muscular Dystrophy Market
- 35. Duchenne Muscular Dystrophy Market High Potential Countries, Segments and Strategies
- 35.1 Duchenne Muscular Dystrophy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Duchenne Muscular Dystrophy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Duchenne Muscular Dystrophy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
- 36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.